US-based RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, has announced an exclusive distributor partnership with MineBio Life Sciences, a trusted partner to China's biopharmaceutical and advanced therapy community.
Under the agreement, MineBio will distribute RoosterBio's full platform of research-grade and CliniControl™ cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio's research use only and cGMP CliniControl™ MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay.
RoosterBio's CliniControl™ product line includes cGMP-manufactured MSC expansion media, exosome collection media, bioreactor feeds, and genetic engineering media designed to support the full continuum of hMSC, secretome, and exosome / extracellular vesicle product development, from early research through cGMP manufacturing. These products are supported by industry leading quality and regulatory documentation, including FDA Type II Master Files and regulatory support dossiers for trials in other jurisdictions. RoosterBio's platform has strong global adoption, supporting GMP manufacturing for numerous trials since 2019 while providing advanced therapy developers with the regulatory support and product consistency required for therapeutic development.
China's regenerative medicine sector has experienced rapid growth, with Chinese institutions and biopharmaceutical companies conducting a significant and growing number of MSC and exosome clinical trials. MineBio's established relationships and expert guidance across China's cell and gene therapy, stem cell, and regenerative medicine sectors position it uniquely to deliver RoosterBio's platform to developers at all stages.
